MedTrace Logo

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy

NCT00700440 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2010-03-26

Study results available
· View outcomes & findings →

Summary

This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

C225 (cetuximab)

one week before and then weekly during radiotherapy

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER

  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Fudan University

    collaborator OTHER

  • Cancer Hospital of Guizhou Province

    collaborator OTHER

  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER

  • Central South University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Tai-xiang Lu, M.D. · Departments of Radiation Oncology, Cancer Center, Sun Yat-sen University

  • Tong-yu Lin, M.D., PhD · Departments of Chemotherapy, Cancer Center, Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00700440 on ClinicalTrials.gov